Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Morgan Stanley said that the company is a distinctive play on shifting lifestyle dynamics, and is largely insulated from ...

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for ...

Ozempic has officially arrived in India at a comparatively affordable price, sparking buzz among diabetes and weight loss ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

The European Medicines Agency (EMA) has recommended extending the use of Mounjaro to younger patients with diabetes, ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Dr Joshi: Vigilance is the key. The drugs must be taken under strict supervision. Common side effects like nausea, vomitting, ...

As Eli Lilly and Novo Nordisk scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, much smaller potential rival Structure Therapeutics spotlighted positive ...

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled WEgovy Real ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...